[{"id":"19be524b-4248-4054-97ea-82c45566fa0d","acronym":"","url":"https://clinicaltrials.gov/study/NCT02540876","created_at":"2021-01-18T12:17:34.359Z","updated_at":"2024-07-02T16:37:00.329Z","phase":"Phase 1","brief_title":"Ilorasertib in Treating Patients With CDKN2A-deficient Advanced or Metastatic Solid Cancers That Cannot Be Removed by Surgery","source_id_and_acronym":"NCT02540876","lead_sponsor":"University of Chicago","biomarkers":" CDKN2A","pipe":" | ","alterations":" CDKN2A deletion • CDKN2A mutation","tags":["CDKN2A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CDKN2A deletion • CDKN2A mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ilorasertib (ABT348)"],"overall_status":"Completed","enrollment":" Enrollment 12","initiation":"Initiation: 09/08/2015","start_date":" 09/08/2015","primary_txt":" Primary completion: 02/08/2019","primary_completion_date":" 02/08/2019","study_txt":" Completion: 02/08/2019","study_completion_date":" 02/08/2019","last_update_posted":"2019-04-22"}]